Trial Profile
Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARISTOPHANES
- Sponsors Bristol-Myers Squibb
- 05 Dec 2023 Status changed from active, no longer recruiting to completed.
- 26 Jan 2022 Planned End Date changed from 31 Dec 2019 to 30 Sep 2022.
- 07 May 2021 Results published in the Advances in Therapy